Demonstrated a Reduction of Symptoms with Short Procedural and Recovery Times Leading Coronary Physiology Experts Appointed Co-Principal Investigators for Planned U.S. Early Feasibility Study SANTA CLARA, Calif., Oct. 28, 2024 /PRNewswire/ — VahatiCor, a leader in cardiovascular…
Coronary/Structural Heart
BioCardia Completes Phase III Randomized Double-Blind Controlled Trial of Autologous Cell Therapy for Ischemic Heart Failure
BioCardia announced today the completion of its last protocol specified follow-up visit in CardiAMP HF multi-center trial.
Impella ECP Pivotal Study Demonstrates Safety, Efficacy for Use in High-Risk PCI
DANVERS, Mass., Oct. 28, 2024 /PRNewswire/ — Results were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference from the first completed pivotal trial on patients supported with Impella ECP™, a novel transvalvular axial flow pump with compressible pump architecture….
JACC: Cardiovascular Interventions Publishes Peer-Reviewed Article on Emerging Hybrid Intracoronary Imaging Technologies
– Conavi Medical’s Novasight Hybrid™ System is the first technology to combine both IVUS and OCT to enable simultaneous and co-registered imaging of coronary arteries –
RAMPART Announces Collaboration with Armery Medical Technologies to Offer Radial Arm Board Solution
RAMPART, a Birmingham-based medical device company specializing in radiation shielding and orthopedic protection, announced a global collaboration agreement with Armery Medical Technologies to manufacture, sell and distribute the Armery Radial Arm Board solution. The Armery solution maximizes support and protection during radial procedures and furthers Rampart’s mission to provide market […]
PROVISION Study, First Ever Prospective RCT of CathWorks FFRangio Outcomes Compared to Invasive Wire-based Physiology in Japan, Meets its Primary Endpoint
PROVISION Study demonstrates significant economic and resource utilization advantages in FFRangio cohort compared to invasive wire-based FFR cohort WASHINGTON, Oct. 27, 2024 /PRNewswire/ — Today at the Cardiovascular Research Foundation’s annual Transcatheter Cardiovascular Therapeutics…
ADONA MEDICAL INITIATES FIRST-IN-HUMAN STUDY WITH ITS NOVEL INTERATRIAL SHUNT FOR PATIENTS WITH HEART FAILURE
Initial cases conducted in the Republic of Georgia with support from leading US cardiologists Adjustable interatrial shunt with integrated bi-atrial pressure monitoring aims to deliver a more personalized lifetime approach to heart failure management LOS GATOS, Calif., Oct. 27, 2024…
ADVANCED NANOTHERAPIES ANNOUNCES POSITIVE RESULTS IN ITS FIRST-IN-HUMAN TRIAL AND PLANS FOR U.S. EARLY FEASIBILITY STUDY FOR SIRPLUX™ DUO DRUG-COATED BALLOON
First-of-its-kind Dual-Drug Therapy for Coronary De Novo Disease Moves Toward U.S. Clinical Phase Novel Nanoparticle Technology Platform Aims to Deliver Two Proven Drugs for Vessel Patency and Restenosis Prevention SANTA CLARA, Calif., Oct. 26, 2024 /PRNewswire/ — Advanced NanoTherapies…
Corvia Medical Announces Three-Year Clinical Trial Results Confirming Significant and Durable Benefits of the Corvia Atrial Shunt in Heart Failure Patients
44% reduction in total heart failure event rate and ongoing improvements in quality of life in responder group patients implanted with shunt TEWKSBURY, Mass., Oct. 25, 2024 /PRNewswire/ — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today…
Medtronic receives CE Mark for Evolut™ FX+ TAVI system for treatment of symptomatic severe aortic stenosis
Medtronic plc, a global leader in healthcare technology, today announced it has received CE (Conformité Européenne) Mark for the Evolut™ FX+ transcatheter aortic valve implantation (TAVI) system, the company’s latest Evolut TAVI system for the treatment of symptomatic severe aortic stenosis. This follows the recent United States Food and Drug […]